Seegnal closes C$416K first tranche, upsizes placement to C$1.85M

What's the deal? SeegnalDealroom has a profile for this one. Try Dealroom →, a Calgary-based clinical decision support software company listed on the TSX Venture Exchange, has closed the first tranche of a non-brokered private placement, raising C$416,220. The company issued 1,486,500 units at C$0.28 each, with each unit comprising one common share and one warrant exercisable at C$0.50 over 36 months.

Why now? Seegnal also secured TSXV approval to upsize and extend the offering to as much as C$1,850,000, or up to 6,607,143 units. The second and final tranche is expected to close on or about September 30, 2026, subject to regulatory approvals.

What's the endgame? Seegnal sells a SaaS platform that helps clinicians prescribe more precisely by integrating patient data — medications, lab results, renal function, allergies, and age — at the point of care. The technology is used by more than 15,000 clinicians daily.

Proceeds from the first tranche will fund general corporate and working capital purposes. No finders' fees were paid, and all securities carry a four-month hold period.

What could go wrong? Insiders subscribed for all 1,486,500 units in the first tranche, making it a related party transaction under Multilateral Instrument 61-101. The company relied on exemptions from valuation and minority approval requirements, and did not file a material change report 21 days ahead of closing because insider participation was unconfirmed at the time.

The signal: The raise is a modest one — at roughly $300,000, it sits near the bottom of comparable venture rounds. For a small-cap healthtech firm, an insider-backed placement signals internal conviction as it works to scale its prescribing-safety platform across healthcare settings.

Read more: Business Insider

Image credit: zhouxuan12345678